Two medication – Pfizer and Merck KGaA’s Bavencio and AstraZeneca’s Imfinzi – noticed Section III trials fail, whilst expected unfavorable effects induced Roche to withdraw Tecentriq from regulatory assessment.



Supply hyperlink

LEAVE A REPLY

Please enter your comment!
Please enter your name here